UK markets closed

Galapagos NV (GLPG)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
75.04-1.12 (-1.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close76.16
Open77.26
Bid75.01 x 800
Ask75.10 x 900
Day's range73.81 - 78.05
52-week range73.81 - 233.14
Volume551,950
Avg. volume331,561
Market cap4.991B
Beta (5Y monthly)0.35
PE ratio (TTM)N/A
EPS (TTM)-5.71
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est94.80
  • Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript
    Motley Fool

    Galapagos NV (GLPG) Q1 2021 Earnings Call Transcript

    GLPG earnings call for the period ending March 31, 2021.

  • Globe Newswire

    Transparency notification received from The Capital Group

    Mechelen, Belgium; 4 May 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a new transparency notification from The Capital Group Companies, Inc. Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 30 April 2021 from The Capital Group Companies, Inc., who notified that it holds 4.65% of the current 65,511,581 outstanding Galapagos shares. The Capital Group Companies, Inc. thus crossed below the 5% threshold of Galapagos’ voting rights by disposing of voting securities on 29 April 2021. The full transparency notice is available on the Galapagos website. About Capital GroupCapital Group controls Capital Bank & Trust Company and Capital Research & Management Company through its direct subsidiary Capital Group International, Inc. (“CGII”), controls four CGII investment management companies (Capital International, Inc.; Capital International Limited, Capital International Sàrl; and Capital International K.K.), which all together hold 3,049,333 of Galapagos’ voting rights, consisting of ordinary shares, which represents 4.65%. About GalapagosGalapagos NV discovers and develops small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises Phase 3 through to discovery programs in inflammation, fibrosis, and other indications. Our ambition is to become a leading global biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com. ContactsInvestors:Elizabeth GoodwinVP Investor Relations+1 781 460 1784 Sofie Van GijselSenior Director Investor Relations+32 485 19 14 15ir@glpg.com Media:Carmen VroonenGlobal Head Communications & Public Affairs+32 473 824 874 Kyra ObolenskySenior Director Corporate Communications+32 491 92 64 35communications@glpg.com 1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market Attachment Transparency notification received from The Capital Group

  • Globe Newswire

    Galapagos creates new subscription right plans

    Mechelen, Belgium; 30 April 2021, 22.01 CET; regulated information –– Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its supervisory board created 2,736,250 subscription rights under new subscription right plans for the benefit of the personnel of the company and its subsidiaries. On 30 April 2021, the supervisory board of Galapagos approved “Subscription Right Plan 2021 BE”, intended for members of personnel of the company and its Belgian subsidiaries, “Subscription Right Plan 2021 RMV”, intended for the employees of its French subsidiary, Galapagos SASU, and “Subscription Right Plan 2021 ROW”, intended for the employees of its other non-Belgian subsidiaries, within the framework of the authorized capital. Under these subscription right plans, 2,736,250 subscription rights were created, subject to acceptances, and offered to the beneficiaries of the plans. The subscription rights have an exercise term of eight years as of the date of the offer and have an exercise price of €64.76 (the closing price of the share on Euronext Amsterdam and Brussels on the day preceding the date of the offer). The subscription rights are not transferable. The subscription rights under Subscription Right Plan 2021 BE can in principle not be exercised prior to 1 January 2025. The subscription rights under Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW vest and become exercisable in instalments: with 25% of each grant being exercisable as of 1 January 2023, 25% as of 1 January 2024 and 50% as of 1 January 2025. Each subscription right gives the right to subscribe to one new Galapagos share. Should the subscription rights be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market. The subscription rights as such will not be listed on any stock market. Galapagos’ total share capital currently amounts to €354,359,437.71; the total number of securities conferring voting rights is 65,511,581, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and all voting rights are of the same category. The total number of rights to subscribe to not yet issued securities conferring voting rights is (i) 6,776,730 subscription rights under several outstanding employee subscription right plans, which equals 6,776,730 voting rights that may result from the exercise of those subscription rights, and (ii) one subscription right issued to Gilead Therapeutics to subscribe for a maximum number of shares that is sufficient to bring the shareholding of Gilead and its affiliates to 29.9% of the actually issued and outstanding shares after the exercise of the subscription right. This excludes the 2,736,250 subscription rights of Subscription Right Plan 2021 BE, Subscription Right Plan 2021 RMV and Subscription Right Plan 2021 ROW, which were created subject to acceptance. Galapagos does not have any convertible bonds or shares without voting rights outstanding. About Galapagos Galapagos NV (Euronext & NASDAQ: GLPG) discovers, develops and commercializes small molecule medicines with novel modes of action, several of which show promising patient results and are currently in late-stage development in multiple diseases. Our pipeline comprises discovery through Phase 3 programs in inflammation, fibrosis and other indications. Our ambition is to become a leading global biotech company focused on the discovery, development and commercialization of innovative medicines. More information at www.glpg.com. Investors:Elizabeth GoodwinVP Investor Relations+1 781 460 1784 Sofie Van GijselSenior Director IR +32 485 19 14 15ir@glpg.com Media:Carmen VroonenGlobal Head of Communications & Public Affairs+32 473 82 48 74 Kyra ObolenskySenior Director Corporate Communications+32 491 92 64 35communications@glpg.com Forward-looking statementsThis release may contain forward-looking statements. Such forward-looking statements are not guarantees of future results. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any forward-looking statements in this document, unless specifically required by law or regulation. Attachment Galapagos creates new subscription right plans